Glycan Therapeutics Corporation

Raleigh, NC Doing business as Biotechnology Research

UEI
KYG3DZSMH4R7
CAGE
6XZ77
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
617 Hutton St #101, Raleigh, NC 27606, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Chemoenzymatic synthesis of heparin sulfate HHSN261201500019C National Cancer Institute (NIH) $1,646,541
Chemoenzymatic synthesis of heparin sulfate oligosaccarides HHSN261201300050C National Cancer Institute (NIH) $299,447

Grant awards

Award Agency Obligated Awarded
Synthesis of the library of heparan sulfate hexasaccharide mimetics R44GM145004 National Institute of General Medical Sciences (NIH) $2,405,558
Sulfated carbohydrates for the treatment of periodontitis R41DE032276 National Institute of Dental and Craniofacial Research (NIH) $695,073
Development of anticoagulant sulfated glycans - sulfated glycan 8-MER is a carbohydrate-based compound with… R44GM148100 National Institute of General Medical Sciences (NIH) $2,507,523
Development of?a sensitive?method to measure heparan sulfate 6-O-endosulfatase - the proposal is aimed to develop a… R43GM149008 National Institute of General Medical Sciences (NIH) $1,049,927
Construction of chondroitin sulfate microarray - project title: construction of chondroitin sulfate microarray the… R43GM140693 National Institute of General Medical Sciences (NIH) $663,268

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Glycoscientific, L.L.C. UEI EUVNNWGFCA87 Athens, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Tega Therapeutics Inc. UEI C1LJLCS3PM51 San Diego, CA 622110 General Medical and Surgical Hospitals
Z Biotech, LLC UEI KTUKAUTZVRJ3 Aurora, CO 541714 Research and Development in Biotechnology (except Nanobiotechnology)
IHP Therapeutics Inc. UEI MASZJLS7DHK3 San Carlos, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Natglycan LLC UEI NMMMHXNPL8U5 Tucker, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Glycan Therapeutics Corporation is a corporate entity that provides research and development services related to glycosaminoglycans through federal grants. The company specializes in synthesizing sulfated carbohydrates such as heparan sulfate using innovative enzyme-based methods.

Glycan Therapeutics has received over $17 million in federal prime and sub awards from the Department of Health and Human Services' National Institutes of Health to support research on glycosaminoglycans. This includes multiple project grants from the National Institute of General Medical Sciences through programs like Biomedical Research and Research Training (CFDA 93.859). Specifically, Glycan Therapeutics develops synthetic heparan sulfate oligosaccharides to serve as research tools and potential therapeutics, quantifies and analyzes glycosaminoglycans from biological sources, and constructs methods to study interactions between sulfated glycans like chondroitin sulfate and proteins. Additional services provided via federal grants include pharmacodynamic analysis in animal models, process development and scale up of chemical manufacturing, and preclinical toxicology studies.

Quick answers

Is Glycan Therapeutics Corporation registered in SAM.gov?

Yes. Glycan Therapeutics Corporation's SAM.gov registration is active through June 24, 2027.

What is Glycan Therapeutics Corporation's CAGE code?

Glycan Therapeutics Corporation's CAGE code is 6XZ77, and its Unique Entity ID (UEI) is KYG3DZSMH4R7.

What is Glycan Therapeutics Corporation's most recent federal award?

Glycan Therapeutics Corporation's most recent federal grant award is Synthesis of the library of heparan sulfate hexasaccharide mimetics (R44GM145004), from National Institute of General Medical Sciences (NIH), on September 21, 2023.

On GovTribe

See Glycan Therapeutics Corporation's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe